Limitations of long term use of antiparkinson drugs.
Effective control of parkinsonian symptoms can be achieved in a substantial number of patients by the judicious use of dopaminergic agents. To a considerable extent these drugs produce optimal therapeutic effects during the first 3-5 years of their use. Subsequently, efficacy diminishes with reemergence of parkinsonian symptoms as well as a number of untoward responses. The nature, frequency and mechanisms underlying the limitations of long term use of presently available anti-parkinson agents are discussed in this presentation.
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005221:Fatigue / Q000150:complications; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D009069:Movement Disorders / Q000139:chemically induced / Q000150:complications; D009440:Neurasthenia / Q000150:complications; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology; D010551:Personality / Q000187:drug effects; D013997:Time Factors
D000978:Antiparkinson Agents